Floatz logo

Eloxatin

Colorectal Cancer Liver Metastases

Shanghai Changzheng HospitalPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Colorectal Cancer Liver Metastases cohort.

Asset / SponsorPhaseRating
Regorafenib
Sun Yat-sen University
Phase 3BB
Irinotecan
Sun Yat-sen University
Phase 3BB
Capecitabine
Shanghai Changzheng Hospital
Phase 2B
(+)-VINCRISTINE
Shanghai Changzheng Hospital
Phase 2CCC
Toripalimab
Sun Yat-sen University
Phase 2CCC
Nivolumab
Shanghai Changzheng Hospital
Phase 2CCC
Cetuximab
Fudan University
N/AD

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →